Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Gritstone bio Inc (NASDAQ:GRTS) announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy for advanced solid tumors.
- 6 of 13 treated patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) had a molecular response. The observed overall survival in this group will now exceed 22 months (median OS not yet reached versus 7.8 months in those without a molecular response).
- Related: Gritstone's Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings.
- This compares to a median overall survival not yet reached and exceeding 18 months, as reported in May 2022.
- 4 of 6 patients with molecular response had liver metastasis.
- All patients had PD-L1 expression <1% and low levels of ifng-related gene expression.< li>
- The median tumor mutational burden was 2.9 and 3.6 mutations/MB in those with and without molecular response, respectively.
- Price Action: GRTS shares are up 10.85% at $2.61 on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!